Snigdha Srivastava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Snigdha Srivastava has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Rajan Kumar Kurmi
Department of Chemistry, Metro College of Health Sciences and Research, Greater Noida, India
3 shared publications - Niti Sharma
Department of Pharmacology, Lloyd Institute of Management and Technology, Greater Noida, India
1 shared publication Pallavi M. Lavhale
Ram-Eesh Institute of Vocational &Technical Education, Greater Noida, Uttar Pradesh, India
1 shared publication- Preeti Yadav
Department of Chemistry, Metro College of Health Sciences and Research, Greater Noida, India
1 shared publication Rajan K. Kurmi
Ram-Eesh Institute of Vocational &Technical Education, Greater Noida, Uttar Pradesh, India
1 shared publicationReema Sinha
Ram-Eesh Institute of Vocational &Technical Education, Greater Noida, Uttar Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 30 January 2026
- Published by Springer Nature in Nutrire
- Vol. 51 (1) , 10
Exploring micronutrient diets in renal disease through metabolomics: a comprehensive review
- 30 January 2026
- Published by Springer Nature in Nutrire
- Vol. 51 (1) , 10
Open AccessExploring micronutrient diets in renal disease through metabolomics: a comprehensive review
- Open Access
- 22 January 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 5
Single-atom catalysts for nano-catalytic tumor therapy: atomic-scale mechanisms in sono-photodynamic therapy
- 22 January 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 5
Open AccessSingle-atom catalysts for nano-catalytic tumor therapy: atomic-scale mechanisms in sono-photodynamic therapy
- Open Access
- 26 March 2024
- Published by MDPI AG in Preprints.org
Synthesis, In silico studies, and biological evaluation of newer N, N'-Phthaloyl GABA Aldehyde/ Aniline analogs as Anti-Epileptic
The main inhibitory neurotransmitter in the mammalian brain is 4-aminobutyric acid (GABA). Phthalimide acts as a sodium channel antagonist, one of the finest targets for treating epilepsy is the sodium channel and JNK kinase activity is inhibited to treat epilepsy. a novel compound with multiple targets of action for the treatment of epilepsy also anti-oxidant activity has been designed. The compounds are designed in two series aldehydes and aniline. Docking of all the designed compounds has been done with the suitable protein GABA-AT, sodium channel, JNK protein, and anti-oxidant from protein bank. QSAR was done for constructing many linear regression models. In combination with the developed Docking and QSAR outcomes, ADMET has been performed for the active compounds. The result shows that 11 of the compounds have excellent binding energy in docking with all the receptors and also have good QSAR results and follow the ADMET. The structural understanding of human GABA-AT inhibition was obtained from molecular dynamics simulation studies for compound no. 11 at 5 nanoseconds. Synthesis and pharmacological activity also suggest that the designed compound no.11 be considered the best Novel Compound.
- 26 March 2024
- Published by MDPI AG in Preprints.org
Open AccessSynthesis, In silico studies, and biological evaluation of newer N, N'-Phthaloyl GABA Aldehyde/ Aniline analogs as Anti-Epileptic
The main inhibitory neurotransmitter in the mammalian brain is 4-aminobutyric acid (GABA). Phthalimide acts as a sodium channel antagonist, one of the finest targets for treating epilepsy is the sodium channel and JNK kinase activity is inhibited to treat epilepsy. a novel compound with multiple targets of action for the treatment of epilepsy also anti-oxidant activity has been designed. The compounds are designed in two series aldehydes and aniline. Docking of all the designed compounds has been done with the suitable protein GABA-AT, sodium channel, JNK protein, and anti-oxidant from protein bank. QSAR was done for constructing many linear regression models. In combination with the developed Docking and QSAR outcomes, ADMET has been performed for the active compounds. The result shows that 11 of the compounds have excellent binding energy in docking with all the receptors and also have good QSAR results and follow the ADMET. The structural understanding of human GABA-AT inhibition was obtained from molecular dynamics simulation studies for compound no. 11 at 5 nanoseconds. Synthesis and pharmacological activity also suggest that the designed compound no.11 be considered the best Novel Compound.
- Open Access
- 20 July 2023
- Published by Ram-Eesh Institute of Vocational and Technical Education in INTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER)
- Vol. 5 (01) , 6-12
In-silico Docking and ADMET: Recent Innovations of Carvone
For the almost 500 decades, naturally occurring plant products always showed a narrative role to society for their effectiveness against several diseases. Carvone is a mono-terpenoid which is obtained as an essential oil obtained from Anethum graveolens (dill) and Carum carvi (caraway) oils, S(+) enantiomer and the (-R) enantiomer of carvone as a primary constituent of Mentha spicata (spearmint) oil also found in Calamintha officinalis (calamint) oil. As Carvone has shown a very less toxic effect. S(+) Carvone also acts as an anti-epileptic agent, (S &R) Carvone has shown much more potent activity when compared to (R) species of carvone. By performing In-silico docking studies of S(+) Carvone it has been observed that it is quite safe and potentially effective as an anticonvulsant agent, antispasmodic agent, antifungal agent, also as a cardiovascular agent etc. Carvone has a high permeability to GI absorption and also it follows the Lipinski rule (0 violations). Although, Carvone has less toxicity while crossing the blood-brain barrier. Docking studies of carvone is suggesting that it can be used for many advancements of the drug to achieve potent results in different pharmacological aspects.
- 20 July 2023
- Published by Ram-Eesh Institute of Vocational and Technical Education in INTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER)
- Vol. 5 (01) , 6-12
Open AccessIn-silico Docking and ADMET: Recent Innovations of Carvone
For the almost 500 decades, naturally occurring plant products always showed a narrative role to society for their effectiveness against several diseases. Carvone is a mono-terpenoid which is obtained as an essential oil obtained from Anethum graveolens (dill) and Carum carvi (caraway) oils, S(+) enantiomer and the (-R) enantiomer of carvone as a primary constituent of Mentha spicata (spearmint) oil also found in Calamintha officinalis (calamint) oil. As Carvone has shown a very less toxic effect. S(+) Carvone also acts as an anti-epileptic agent, (S &R) Carvone has shown much more potent activity when compared to (R) species of carvone. By performing In-silico docking studies of S(+) Carvone it has been observed that it is quite safe and potentially effective as an anticonvulsant agent, antispasmodic agent, antifungal agent, also as a cardiovascular agent etc. Carvone has a high permeability to GI absorption and also it follows the Lipinski rule (0 violations). Although, Carvone has less toxicity while crossing the blood-brain barrier. Docking studies of carvone is suggesting that it can be used for many advancements of the drug to achieve potent results in different pharmacological aspects.